Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmology Contract Research Organization Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.
The ophthalmology contract research organization market has experienced significant growth, increasing from $2.73 billion in 2024 to $2.97 billion in 2025, with a compound annual growth rate (CAGR) of 8.5%. Key drivers of this expansion include rising cases of vision-related diseases, an aging global population, and the globalization of clinical research. Additionally, increased incidents of chronic illnesses such as diabetes have contributed to the market's historical growth trajectory.
Looking forward, the market is anticipated to reach $4.07 billion by 2029, boasting a CAGR of 10.4%. This growth will be propelled by the adoption of decentralized clinical trial models, an uptick in R&D for ophthalmic medical devices, and greater investments in precision medicine. Pediatric eye care research and venture capital influx in eye health startups further support this upward trend. Cutting-edge advancements such as AI-powered diagnostics, 3D retinal imaging, and cloud-based trial management platforms are expected to drive innovations in this arena.
With the prevalence of eye disorders expected to rise, the ophthalmology CRO market is poised for expansion. Age-related conditions such as cataracts, glaucoma, macular degeneration, and diabetic retinopathy are increasingly common. Ophthalmology CROs are crucial in advancing treatments by accelerating the development, testing, and approval of eye-related therapies. For example, in 2022, England recorded 22,552 new certifications for vision impairment, highlighting the urgent need for effective solutions.
Prominent players in the market focus on creating innovative solutions like integrated trial platforms, which streamline clinical studies and improve data management. One such innovation, introduced by Lindus Health Limited, is the Citrus trial platform. This system optimizes patient recruitment, eConsent, data capture, and more, enhancing trial efficiency and regulatory compliance.
Recent market developments include strategic acquisitions aimed at enhancing service offerings. In January 2024, Iuvo Bioscience LLC acquired Promedica International, expanding its capabilities in ophthalmic clinical research services. This acquisition underscores the industry's focus on comprehensive support from preclinical to all clinical stages.
Major market players include IQVIA Holdings, Eurofins Scientific, Syneos Health, Charles River Laboratories, and Parexel International. North America leads the market, while Europe is predicted to witness the fastest growth. Key regions covered in market reports include Asia-Pacific, Western and Eastern Europe, North America, South America, and the Middle East and Africa, with coverage of countries such as the USA, UK, China, and Germany.
The ophthalmology CRO market comprises a range of services: early phase development, clinical research, regulatory consulting, and strategic advisory services. These services cater to pharmaceutical companies, medical device manufacturers, and research institutions, helping them navigate the complexities of ophthalmic drug and device development.
Overall, the ophthalmology CRO market demonstrates robust growth potential, driven by technological advancements, demographic shifts, and increased investment in eye health solutions. As the demand for innovative ophthalmic treatments rises, CROs will play a pivotal role in the future of eye care research and development.
Key Reasons to Purchase:
- Attain a global perspective with coverage of 15 geographies.
- Analyze the influence of macro factors including conflicts, pandemics, recovery, inflation, interest rates, and political shifts.
- Develop regional and country strategies guided by localized data and analysis.
- Identify high-potential growth segments for investment opportunities.
- Leverage forecast data to outperform competitors and stay ahead of industry trends.
- Gain insights into consumer dynamics and market share leadership.
- Benchmark against major competitors with reliable, high-quality market data.
- Utilize the report for internal and external presentations, equipped with up-to-date data and analysis.
- Receive the report along with an Excel data sheet for easy data interpretation and extraction.
- Access all report data through an Excel dashboard format.
Scope:
- Service Type: Early Phase Development Services, Clinical Research, Laboratory Services, Regulatory Consulting Services
- Therapy: Traditional and Advanced Interventions, Anti-Inflammatory Treatments
- End-User: Pharma/Biopharma companies, Medical Device Companies, Academic Institutes
Companies Featured
- IQVIA Holdings Inc.
- Eurofins Scientific SE
- Syneos Health Inc.
- Charles River Laboratories International Inc.
- Parexel International Corporation
- Fortrea Holdings Inc.
- Medpace Holdings Inc.
- PSI CRO AG
- Worldwide Clinical Trials
- The Emmes Company LLC
- TFS HealthScience
- QPS Holdings LLC
- ProTrial Research Inc.
- Lexitas Pharma Services Inc.
- Covance Inc.
- Cliantha Research Limited
- Trial Runners
- Iris Pharma
- WuXi AppTec Co. Ltd.
- ORA Inc.
- Novotech Health Holdings Pty Limited
For more information about this report visit https://www.researchandmarkets.com/r/2lhpgu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
